NADAC acquisition cost data for TRUVADA 200 MG-300 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 61958070101 | $59.54 | 2022-07-20 | Rx |
| 61958070101 | $59.54 | 2022-07-20 | Rx |
| 61958070101 | $59.54 | 2022-07-20 | Rx |
| 61958070101 | $59.54 | 2022-07-20 | Rx |
| 61958070101 | $59.54 | 2022-07-20 | Rx |
| 61958070101 | $59.54 | 2022-07-20 | Rx |
| 61958070101 | $59.54 | 2022-07-20 | Rx |
| 61958070101 | $59.54 | 2022-07-20 | Rx |
| 61958070101 | $59.54 | 2022-07-20 | Rx |
| 61958070101 | $59.54 | 2022-07-20 | Rx |
Generic: Emtricitabine/Tenofovir (Tdf) | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $247.1M | 130,480 | 20,878 | $59.29 |
| 2020 | $164.3M | 79,859 | 13,732 | $62.56 |
| 2021 | $36.3M | 19,286 | 4,257 | $61.70 |
| 2022 | $9.1M | 4,499 | 1,291 | $60.70 |
| 2023 | $5.5M | 2,536 | 588 | $61.87 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Florida | $1.1M | 595 | 210 |
| New York | $860.2K | 401 | 73 |
| California | $615.1K | 233 | 52 |
| Texas | $380.9K | 175 | 36 |
| Illinois | $259.7K | 83 | 16 |
| Pennsylvania | $236.7K | 105 | 20 |
| New Jersey | $146.2K | 67 | N/A |
| Michigan | $135.7K | 56 | 11 |
| Ohio | $128.0K | 55 | 15 |
| North Carolina | $124.8K | 57 | 13 |
| Virginia | $111.9K | 44 | 11 |
| Connecticut | $110.0K | 48 | N/A |
| Arizona | $106.7K | 46 | 13 |
| Kentucky | $90.1K | 49 | N/A |
| Tennessee | $88.1K | 45 | N/A |
| Massachusetts | $87.7K | 42 | N/A |
| Missouri | $87.1K | 44 | N/A |
| Maryland | $83.3K | 34 | N/A |
| Washington | $75.9K | 23 | N/A |
| Louisiana | $65.9K | 29 | N/A |
| Georgia | $64.5K | 41 | N/A |
| Oregon | $58.4K | 32 | N/A |
| Indiana | $51.6K | 21 | N/A |
| Colorado | $48.5K | 25 | N/A |
| Wisconsin | $47.7K | 18 | N/A |
| Mississippi | $47.5K | 24 | N/A |
| Puerto Rico | $41.5K | 22 | N/A |
| Maine | $34.7K | 15 | N/A |
| Iowa | $29.7K | 15 | N/A |
| Nevada | $26.8K | 15 | N/A |
| Nebraska | $23.7K | 12 | N/A |
| Arkansas | $21.0K | 11 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.